SNAP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
SNAP is not a good buy right now. Price action is in a clear downtrend with worsening momentum (bearish MAs and a negatively expanding MACD histogram). Even though the stock looks short-term oversold and options positioning is call-skewed, there is no Intellectia buy signal to prioritize, and an earnings catalyst is imminent (2026-02-04 AH). For an impatient buyer who wants to enter immediately, the risk/reward is unfavorable versus waiting for confirmation of a trend reversal.
Trend/momentum: Bearish. Moving averages are stacked bearishly (SMA_200 > SMA_20 > SMA_5), indicating a sustained downtrend. MACD histogram is negative (-0.0796) and expanding lower, which typically signals increasing downside momentum.
Overbought/oversold: RSI_6 is 24.711, which implies short-term oversold conditions (even if labeled “neutral” in the feed, sub-30 typically signals oversold). This can produce dead-cat bounces, but it is not a reversal signal by itself.
Key levels: Pivot 7.401 is overhead; the stock (6.97) is below pivot and below S1 (7.07), which is bearish. Next support is near S2 6.866 (very close). If 6.866 breaks decisively, downside risk increases. Immediate resistance zones are 7.40–7.73 (pivot/R1). A credible “buy now” setup would require reclaiming and holding above ~7.40 and improving MACD/MA structure.
Pattern-based probabilities (from provided model): modest upside bias next week (+3.98%) but small edge and not strong enough to override the dominant downtrend.
on 2026-02-04 after hours can re-rate the stock quickly if ad trends, subscriptions (Snapchat+), or guidance surprise positively.
• Technical deterioration: Downtrend confirmed by bearish MA stack and negatively expanding MACD histogram—this is the biggest near-term headwind.
• Litigation/regulatory overhang (sector-wide but relevant): The teen mental health/social media trial focusing on Meta/YouTube (with TikTok exiting) keeps scrutiny on social platforms; negative headlines can pressure multiples/sentiment.
• Fundamental quality: Despite revenue growth, losses worsened YoY (net income and EPS declines), which limits how aggressively investors may “buy the dip.”
• Near-term execution risk into earnings (2026-02-04 AH): If guidance disappoints, supports near 6.87 may fail quickly.
Latest reported quarter: 2025/Q3. • Revenue: $1.5068B, +9.78% YoY (solid top-line growth). • Profitability: Net income -$103.5M (more negative YoY; down -32.44%), indicating losses widened. • EPS: -$0.06 (down -33.33% YoY), also worse. • Gross margin: 55.26%, +3.39% YoY (a bright spot—better unit economics), but not yet translating into improving bottom-line results.
Bottom line: Growth is present, margins improved, but earnings power remains weak and deteriorated YoY—this reduces the conviction to buy aggressively during a technical downtrend.
Recent trend (ratings/targets): Predominantly Neutral / In Line across major firms. After Q3, several targets were raised (e.g., $10–$13), but more recently targets have been trimmed into early 2026 (UBS to $9 from $10; Guggenheim to $8.50 from $9), reflecting tempered expectations.
Wall Street pros: • Improving operating discipline/EBITDA narrative post-Q3. • Revenue diversification: Snapchat+ subscription momentum and the Perplexity partnership (noted by multiple firms) as a potential 2026 driver. • AR/AI initiatives can re-ignite engagement/monetization if execution lands.
Wall Street cons: • Concerns about usage growth headwinds and below-peer core ad growth (explicitly cited by Guggenheim). • North America growth remains a recurring concern.
Influential / political trading check: • Hedge funds: Neutral; no significant trend last quarter. • Insiders: Neutral; no significant trend last month. • Congress trading (last 90 days): No data / no recent activity reported.
Net: Street stance is cautious-neutral; targets above the current price imply upside if execution improves, but recent trims and neutral ratings align with a ‘not yet’ setup.
